{"organizations": [], "uuid": "94907f8764801ddecd88a3b9ea75a86d70d0e678", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-edge-therapeutics-provides-update/brief-edge-therapeutics-provides-update-following-interim-analysis-idUSASC09TXI", "country": "US", "domain_rank": 408, "title": "BRIEF-Edge Therapeutics Provides Update Following Interim Analysis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T14:30:00.000+03:00", "replies_count": 0, "uuid": "94907f8764801ddecd88a3b9ea75a86d70d0e678"}, "author": "", "url": "https://www.reuters.com/article/brief-edge-therapeutics-provides-update/brief-edge-therapeutics-provides-update-following-interim-analysis-idUSASC09TXI", "ord_in_thread": 0, "title": "BRIEF-Edge Therapeutics Provides Update Following Interim Analysis", "locations": [], "entities": {"persons": [{"name": "eiko", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-edge therapeutics provides update following interim analysis r", "sentiment": "negative"}, {"name": "brief-edge therapeutics provides update following interim analysis", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "dmc", "sentiment": "none"}, {"name": "therapeutics inc", "sentiment": "none"}, {"name": "newton", "sentiment": "none"}, {"name": "edge therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 30 AM / Updated 16 minutes ago BRIEF-Edge Therapeutics Provides Update Following Interim Analysis Reuters Staff 1 Min Read \nMarch 28 (Reuters) - Edge Therapeutics Inc: \n* EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE \n* EDGE THERAPEUTICS INC - STUDY UNLIKELY TO ACHIEVE PRIMARY EFFICACY ENDPOINT; DMC RECOMMENDS DISCONTINUATION OF STUDY \n* EDGE THERAPEUTICS INC - NO UNEXPECTED SAFETY FINDINGS IN STUDY \n* EDGE THERAPEUTICS INC - EDGE TO REDUCE COSTS AND EVALUATE NEXT STEPS \n* EDGE THERAPEUTICS - PHASE 3 STUDY OF EG-1962 SHOWED LOW PROBABILITY OF ACHIEVING STATISTICALLY-SIGNIFICANT DIFFERENCE VERSUS STANDARD OF CARE \n* EDGE THERAPEUTICS - DATA MONITORING COMMITTEE RECOMMENDED STUDY BE STOPPED BASED ON CONCLUSION THAT STUDY HAS LOW PROBABILITY OF MEETING PRIMARY ENDPOINT \n* EDGE THERAPEUTICS - ANTICIPATES IN NEAR TERM REDUCING SCOPE OF OPERATIONS, INCLUDING SIZE OF WORKFORCE, IN ORDER TO PRESERVE CASH RESOURCES \n* EDGE THERAPEUTICS INC - HAS DECIDED TO DISCONTINUE NEWTON 2 STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T14:30:00.000+03:00", "crawled": "2018-03-28T14:54:08.000+03:00", "highlightTitle": ""}